Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2016 1
2017 2
2018 12
2019 26
2020 16
2021 15
2022 15
2023 15
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

88 results

Results by year

Filters applied: . Clear all
Page 1
Hepatotoxicity in patients with non-small cell lung cancer treated with sotorasib after prior immunotherapy: a comprehensive clinical and pharmacokinetic analysis.
Ernst SM, Hofman MM, van der Horst TE, Paats MS, Heijboer FWJ, Aerts JGJV, Dumoulin DW, Cornelissen R, von der Thüsen JH, de Bruijn P, Hoop EO, Mathijssen RHJ, Koolen SLW, Dingemans AC. Ernst SM, et al. Among authors: hoop eo. EBioMedicine. 2024 Apr;102:105074. doi: 10.1016/j.ebiom.2024.105074. Epub 2024 Mar 19. EBioMedicine. 2024. PMID: 38507877 Free PMC article.
The interplay between tamoxifen and endoxifen plasma concentrations and coagulation parameters in patients with primary breast cancer.
Buijs SM, van Dorst DCH, Kruip MJHA, van den Akker RFP, Cheung KL, Porrazzo R, Oomen-de Hoop E, Jager A, Koolen SLW, Versmissen J, Jan Danser AH, Versteeg HH, Bos MHA, Mathijssen RHJ. Buijs SM, et al. Among authors: oomen de hoop e. Biomed Pharmacother. 2024 Jan;170:115969. doi: 10.1016/j.biopha.2023.115969. Epub 2023 Dec 2. Biomed Pharmacother. 2024. PMID: 38042112 Free article.
A common germline variant in CYP11B1 is associated with adverse clinical outcome of treatment with abiraterone or enzalutamide.
Buck SAJ, Meertens M, van Ooijen FMF, Oomen-de Hoop E, de Jonge E, Coenen MJH, Bergman AM, Koolen SLW, de Wit R, Huitema ADR, van Schaik RHN, Mathijssen RHJ. Buck SAJ, et al. Among authors: oomen de hoop e. Biomed Pharmacother. 2023 Dec 31;169:115890. doi: 10.1016/j.biopha.2023.115890. Epub 2023 Nov 21. Biomed Pharmacother. 2023. PMID: 37988848 Free article.
Proof-of-concept study linking ex vivo sensitivity testing to neoadjuvant anthracycline-based chemotherapy response in breast cancer patients.
Ladan MM, Meijer TG, Verkaik NS, de Monye C, Koppert LB, Oomen-de Hoop E, van Deurzen CHM, Kanaar R, Nonnekens J, van Gent DC, Jager A. Ladan MM, et al. Among authors: oomen de hoop e. NPJ Breast Cancer. 2023 Sep 30;9(1):80. doi: 10.1038/s41523-023-00583-6. NPJ Breast Cancer. 2023. PMID: 37777518 Free PMC article.
Irinotecan-Induced Toxicity: A Pharmacogenetic Study Beyond UGT1A1.
de With M, van Doorn L, Kloet E, van Veggel A, Matic M, de Neijs MJ, Oomen-de Hoop E, van Meerten E, van Schaik RHN, Mathijssen RHJ, Bins S. de With M, et al. Among authors: oomen de hoop e. Clin Pharmacokinet. 2023 Nov;62(11):1589-1597. doi: 10.1007/s40262-023-01279-7. Epub 2023 Sep 16. Clin Pharmacokinet. 2023. PMID: 37715926 Free PMC article.
CBD-oil as a potential solution in case of severe tamoxifen-related side effects.
Buijs SM, Braal CL, Buck SAJ, van Maanen NF, van der Meijden-Erkelens LM, Kuijper-Tissot van Patot HA, Hoop EO, Saes L, van den Boogerd SJ, Struik LEM, van Rossum-Schornagel QC, Mathijssen RHJ, Koolen SLW, Jager A. Buijs SM, et al. Among authors: hoop eo. NPJ Breast Cancer. 2023 Aug 5;9(1):63. doi: 10.1038/s41523-023-00570-x. NPJ Breast Cancer. 2023. PMID: 37543688 Free PMC article.
CYP3A4*22 Genotype-Guided Dosing of Kinase Inhibitors in Cancer Patients.
van Eerden RAG, IJzerman NS, van Meekeren M, Oomen-de Hoop E, Guchelaar NAD, Visser AMW, Matic M, van Schaik RHN, de Bruijn P, Moes DAR, Jobse PA, Gelderblom H, Huitema ADR, Steeghs N, Mathijssen RHJ, Koolen SLW; Dutch Pharmacology Oncology Group. van Eerden RAG, et al. Among authors: oomen de hoop e. Clin Pharmacokinet. 2023 Aug;62(8):1129-1139. doi: 10.1007/s40262-023-01260-4. Epub 2023 Jun 13. Clin Pharmacokinet. 2023. PMID: 37310647 Free PMC article.
mFast-SeqS-based aneuploidy score in circulating cell-free DNA is a prognostic biomarker in prostate cancer.
Isebia KT, Mostert B, Deger T, Kraan J, de Weerd V, Oomen-de Hoop E, Hamberg P, Haberkorn BCM, Helgason HH, de Wit R, Mathijssen RHJ, Lolkema MP, Wilting SM, van Riet J, Martens JWM. Isebia KT, et al. Among authors: oomen de hoop e. Mol Oncol. 2023 Sep;17(9):1898-1907. doi: 10.1002/1878-0261.13449. Epub 2023 Aug 18. Mol Oncol. 2023. PMID: 37178439 Free PMC article.
88 results